KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Share-based Compensation: 2017-2025

Historic Share-based Compensation for Twist Bioscience (TWST) over the last 8 years, with Sep 2025 value amounting to $16.1 million.

  • Twist Bioscience's Share-based Compensation rose 30.26% to $16.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.5 million, marking a year-over-year increase of 26.58%. This contributed to the annual value of $64.5 million for FY2025, which is 26.58% up from last year.
  • Per Twist Bioscience's latest filing, its Share-based Compensation stood at $16.1 million for Q3 2025, which was up 0.16% from $16.1 million recorded in Q2 2025.
  • Twist Bioscience's Share-based Compensation's 5-year high stood at $22.5 million during Q1 2022, with a 5-year trough of -$2.3 million in Q4 2022.
  • Over the past 3 years, Twist Bioscience's median Share-based Compensation value was $12.3 million (recorded in 2024), while the average stood at $13.5 million.
  • As far as peak fluctuations go, Twist Bioscience's Share-based Compensation plummeted by 112.84% in 2022, and later skyrocketed by 573.98% in 2023.
  • Twist Bioscience's Share-based Compensation (Quarterly) stood at $18.1 million in 2021, then plummeted by 112.84% to -$2.3 million in 2022, then surged by 573.98% to $11.0 million in 2023, then grew by 8.81% to $12.0 million in 2024, then soared by 30.26% to $16.1 million in 2025.
  • Its Share-based Compensation was $16.1 million in Q3 2025, compared to $16.1 million in Q2 2025 and $20.3 million in Q1 2025.